Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

povetacicept

PharmaDeviceNews povetacicept

Otsuka’s VOYXACT Phase 3 VISIONARY results showed sustained kidney function benefits in adults with IgA nephropathy, strengthening the case for long-term disease modification and full regulatory approval. Representative image.

Pharma & Biotech

Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy

by Pallavi Madhiraju
October 24, 2026
0 Comments

Vertex's RAINIER trial shows 52% proteinuria reduction with povetacicept ahead of a November 30 FDA decision. Can it stand out in IgA nephropathy?

Read More

Latest news and features

Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy
What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research?
Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab
Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Viridian Therapeutics’ FDA-approved Lumvoa enters the thyroid eye disease market with a five-infusion treatment course, intensifying competition with Tepezza. Representative image.

Medical Devices & Diagnostics

FDA approves Genentech’s ENSPRYNG as first at-home treatment for thyroid eye disease

October 18, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Latest business and industry news

Minnesota says Trump administration halted evidence sharing in Renee Good and Alex Pretti killings
Kering plunges 16% as Gucci sales fall 6%. Can 125 store closures fix the brand?
American Express profit rises 28% yet 3,500 jobs are going. What is AXP trying to fix?
Best Version Media names Chris Laurence CEO as Kevin O’Brien shifts to revenue leadership role
Civista Bancshares (CIVB) adds Firelands Health CEO Jeremy Normington-Slay to board as profits grow

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.